Just getting home after an incredible week at FASEB hematologic malignancies. This is truly the best meeting and I feel so lucky to be able to attend!! The week was too busy to actively post so here’s a little recap thread… #HEMSRC 🩸🔬

So excited to share a pre-print of my thesis work! Check it out to see how we can leverage an epigenetic resistance mechanism to PI3K inhibitors to target leukemic stem cells!! (Spoiler alert: PRC2 is involved!) Really proud of this work conducted with @gritsmanlab.bsky.social

bioRxiv Cancer Bio@biorxiv-cancer.bsky.social · last yr.

Exploiting an Epigenetic Resistance Mechanism to PI3 Kinase Inhibition in Leukemic Stem Cells https://www.biorxiv.org/content/10.1101/2025.07.11.663968v1

Stood up for science in Boston today!! Science saves lives! Keep fighting 🧬🤓💪

📣Life update📣!! This week I officially started as a postdoc in the Tothova Lab at @danafarber.bsky.social !! So excited to be surrounded by so many amazing scientists doing cutting edge research 👩‍🔬👨‍🔬 Please share your postdoc advice and of course any Boston recs!!

So sad I am missing #ASH2024 But if you’re there early enough be sure to check out the wonderful @gritsmanlab.bsky.social present exciting updates from my work at the therapy resistance workshop on Friday! 2-5pm in SDCC room 33!

Overwhelmed by all of the exciting new research on chromatin modifiers in AML? Find it hard to keep track of all the new menin inhibitors? Well good news, we’ve just published the perfect review for you in SCTM! @alexkschurer.bsky.social @gritsmanlab.bsky.social academic.oup.com/stcltm/advan...

Targeting chromatin modifying complexes in acute myeloid leukemia

Abstract. Acute myeloid leukemia (AML) is a devastating hematologic malignancy with high rates of relapse, which can, in part, be attributed to the dysregu

academic.oup.com